

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Role and potentials of low-flow CO<sub>2</sub> removal system in mechanical ventilation.

### **This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/135515> since

*Published version:*

DOI:10.1097/MCC.0b013e32834f17ef

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



# UNIVERSITÀ DEGLI STUDI DI TORINO

***This is an author version of the contribution published on:***

*Questa è la versione dell'autore dell'opera:*

*[Current Opinion in Critical Care, 18,1,2012, DOI:*

*10.1097/MCC.0b013e32834f17ef]*

***The definitive version is available at:***

*La versione definitiva è disponibile alla URL:*

*[[http://ovidsp.tx.ovid.com/sp-](http://ovidsp.tx.ovid.com/sp-3.11.0a/ovidweb.cgi?&S=GPGMFPKJGNDDGMIPNCMKJDOBCHLMAA00&Browse=Toc+Children|YES|S.sh.22.23.27.28|98|50)*

*3.11.0a/ovidweb.cgi?&S=GPGMFPKJGNDDGMIPNCMKJDOBCHLMAA00  
&Browse=Toc+Children|YES|S.sh.22.23.27.28|98|50]*

## **Role and potentials of low flow CO<sub>2</sub> removal system in mechanical ventilation**

Pierpaolo Terragni, Giorgia Maiolo *and* V. Marco Ranieri

Address for correspondence and reprint requests:

V.Marco Ranieri, MD

University of Turin

Department of Anesthesia and Intensive Care Medicine

S.Giovanni Battista Molinette Hospital

Corso Dogliotti 14, 10126 Torino Italy

phone + 39 011 6335501

fax + 39 011 6960448

*e-mail:* [marco.ranieri@unito.it](mailto:marco.ranieri@unito.it)

Department of Anesthesia and Intensive Care Medicine  
S.Giovanni Battista Hospital, University of Turin, Italy

## ABSTRACT

**Purpose of review:** An analysis of the technological implementation of extracorporeal CO<sub>2</sub> removal (ECCO<sub>2</sub>R ) techniques, and of its clinical application. A new classification of ECCO<sub>2</sub>R based on technological aspects, clinical properties and physiological performances, is proposed.

**Recent findings:** The use of a ventilation with lower tidal volumes have been proved successful in Acute Respiratory Distress Syndrome (ARDS) patients but can be extremely problematic, especially when dealing with respiratory acidosis. The implementation of extracorporeal CO<sub>2</sub> removal devices can represent the missing link between prevention of ventilator induced lung injury and pH control. ECCO<sub>2</sub>-R has attracted increasing interest because new less invasive approaches allowing an easier management of ARDS patients. Recent studies have also shown that ECCO<sub>2</sub>-R can also be used in patients with exacerbation of Chronic Obstructive Pulmonary Disease (COPD) and as bridge to lung transplantation.

**Summary:** *The future ventilatory management of patients with acute respiratory failure may include a minimally invasive extracorporeal carbon dioxide removal circuit associated with the least amount of ventilatory support (non-invasive in COPD and/or invasive in ARDS) to minimize sedation, prevent ventilator-induced acute lung injury, and nosocomial infections. Randomized clinical trials in the pipeline will confirm this fascinating hypothesis.*

**Key words:** Extra-Corporeal CO<sub>2</sub>Removal (ECCO<sub>2</sub>R); ECMO; protective ventilation; lung support; ventilator induced lung injury (VILI).

Mechanical ventilation (MV) is the main form of life support for patients with acute respiratory failure, and can resolve the impairment of gas exchange alteration in the vast majority patients with acute respiratory failure.[1] However, evidences have progressively emerged suggesting that MV, although indispensable for survival, may worsen the injured lung and may increase mortality rate if inappropriately administered.[2, 3] This is particularly true for acute respiratory distress syndrome (ARDS), where several studies demonstrated that the main reason for high mortality (30-50%) is not the severe hypoxemia but rather multi-organ failure (kidneys, heart, liver, etc.), potentially caused by the translocation of various mediators from the lungs through the systemic circulation to peripheral organs caused and/or augmented by artificial ventilation (ventilator-induced lung injury, VILI).

The randomized trial carried out by the National Institute of Health demonstrated that ventilating patients with a tidal volume ( $V_T$ ) of 6 ml/kg (calculated from predicted body weight, PBW), and with a maximum end-inspiratory plateau pressure ( $P_{PLAT}$ ) of 30 cmH<sub>2</sub>O instead of ventilating patients with a  $V_T$  of 12 ml/kg PBW decreased mortality from

39.8% to 31%. [4] However, observational studies carried out in Europe and in the US demonstrated that there was poor compliance by clinicians in reducing ventilation volumes and pressures in order to minimize iatrogenic damage caused by mechanical ventilation. A major reason for the underuse of protective ventilatory strategies is the hypercapnia caused by the reduction in ventilatory volumes. Furthermore, recent studies have shown that lung hyperinflation still occurs in approximately 30% of ARDS patients even though they are being ventilated “correctly” using the ARDSNet strategy [5]. These studies also suggested that some patients may benefit from a further reduction of  $V_T$  even when  $P_{PLAT}$  is less than 30 cmH<sub>2</sub>O. [5, 6] Bellani and coworkers recently assessed the intensity of pulmonary inflammation during mechanical ventilation using positron-emission tomography (PET) imaging of (18F) fluoro-2-deoxy-D-glucose to detect the presence of metabolically active inflammatory cells. [7] They showed that  $P_{PLAT}$  is significantly correlated with metabolic activity, and the correlation increases steeply above 26-27 cmH<sub>2</sub>O thus suggesting that further limitation of ventilation to values of  $P_{PLAT}$  of 25 cmH<sub>2</sub>O or lower may be associated with lower degree of pulmonary inflammation due to less VILI. [7] (\*\*).

The idea of partial support (removing only carbon dioxide, with little to no impact on oxygenation: partial extracorporeal support) was proposed in 1977 by Kolobow [8, 9] and Gattinoni.[10] These authors suggested that applying only a few ventilator breaths at low volumes and low peak inspiratory pressures (“lung rest”) could prevent damage to the compromised lungs. To reduce complexity, expenses, and side effects of extracorporeal lung assistance, Pesenti and coworkers modified an extracorporeal circuit designed for renal replacement therapy by adding to the circuit an oxygenator and proposed the concept of removing “*only a portion of carbon dioxide production*” to allow less traumatic ventilator settings.[11] This hypothesis was developed taking into consideration the original observation of Sherlock and coworkers who found that patients treated with haemodialysis experienced a transient hypocapnia, hypoventilation and hypoxemia due to the capacity of the hemofilter to remove a significant amount of CO<sub>2</sub>. [12] What Kolobow, Gattinoni and Pesenti therefore proposed may be interpreted nowadays as the optimal protective ventilatory strategy that, “disconnecting” oxygenation (provided using the “residual” functional lungs using PEEP and high

FiO<sub>2</sub>) from CO<sub>2</sub> clearance (performed used extracorporeal circuit and membrane lungs), may minimize/prevent VILI.

## **CARBON DIOXIDE REMOVAL: PHISIOLOGY AND TECHNIQUES**

The use of extracorporeal circuits to support respiratory functions may be described using a “*continuous model*” that analyze and integrates the technological aspects (type of pump, characteristics of the oxygenator, type and size of catheter), the clinical properties (kind of surgical approach) and the physiological performances (amount of oxygen transferred to the patient and of carbon dioxide removed from the patient).[13] (**Table 1**).

The lowest complexity level is represented by **renal support** that requires very low blood flows, is less invasive for the patients requiring low primer volumes and a small coaxial catheter. With this technique carbon dioxide is extracted although a very low levels.[12, 14]

At the other extreme of the complexity scale, **total extracorporeal support (ECMO)** is able to completely supply the physiological blood gas exchanges, normally performed by the native lungs and is therefore capable of delivering oxygen and of removing CO<sub>2</sub> equal to the entire metabolic needs of the patient. It is an invasive and complex system, which needs high blood flows (equivalent to the entire cardiac output) and high diameter cannulation. It is also necessary to use high heparin dosage and elevated volume of priming. This device can be connected to patient with a venous-arterial (V-A) setting, therefore in parallel with the pulmonary circulation, also able to support the cardiac function, or in a venous-venous (V-V) setting, sequentially to the pulmonary circulation, preferred in case on respiratory failure alone.

**Partial extracorporeal support (ECCO<sub>2</sub>-R)** represents the intermediate level of technical complexity. V-V ECCO<sub>2</sub>R needs a 14Fr coaxial catheter, to allow a blood flow of 0.3-0.5 l/min that is constantly guarantee by a roller non-occlusive pump designed to minimize hemolysis; blood is driven through an oxygenator membrane, which is connected to an oxygen source of 6-8 l/min. Some devices also include an hemofilter in series with the oxygenator to allow the extraction of

plasmatic water that is then reinfused in the circuit in order to lower hematocrit and prevent blood clotting.[15, 16] (\*\*)

A centrifugal pump, that creates a radial flow going through an annular fiber oxygenator, has also been used in other veno-venous ECCO<sub>2</sub>R systems. This design maximizes the exchange surface, and therefore the device efficiency.[15] Both technological implementations are able to remove up to 25% of carbon dioxide production, and can transfer no more than 10 ml/min of oxygen. Low dose of heparin (4-18 IU/min) are necessary to avoid clotting occurrence.[15-17]

## **CLINICAL USE OF ECCO<sub>2</sub>R**

A brief overview of past years studies exploring ECCO<sub>2</sub>R techniques safety and feasibility is shown in Table 2.

### ***ARDS***

Gattinoni and coworkers reported the first systematically collected clinical experience of the use of ECCO<sub>2</sub>R in patients with severe ARDS. MV was limited to apneic oxygenation and to 3-5 sighs every minute with a peak inspiratory pressure < 35-45 cmH<sub>2</sub>O; PEEP ranged between

15 and 25 cmH<sub>2</sub>O. Carbon dioxide removal was performed using a pump-driven veno-venous bypass allowing blood flow to pass through two membrane lungs (9 m<sup>2</sup> total membrane surface area). Extracorporeal blood flow was progressively increased from 200 to 300 mL/min to the selected maintenance flow (20-30 % of cardiac output). Although the observed mortality rate was lower than expected, there was no concurrent randomized control group; as well, several episodes of severe bleeding were reported.[18] In 1993 Brunet and coworkers achieved a mortality rate of 50% in ARDS patients, utilizing a V-V ECCO<sub>2</sub>R coupled with protective ventilation that reached a maximum tidal volume of 325ml. They also reported a 21% of hemorrhagic events and an 8% of peripheral vascular problems.[19] One year later, Morris and coworkers presented results of a randomized controlled trial in ARDS patients that investigated the use of Pressure Controlled Inverse-Ratio Ventilation vs ECCO<sub>2</sub>R techniques associated to MV. The trial, showing no significant difference in survival (38%) between the two groups, also highlighted numerous episodes of severe bleeding and the need of major anticoagulation with consequent hemorrhagic complications.[20]

In 2006 Bein and coworkers published a retrospectively experience with an artero-venous pumpless device with an interposed membrane oxygenator sustained by patients hemodynamic. This artificial lung was able to remove up to 50% of the total body CO<sub>2</sub> production, with a blood flow of around 1-2 l/min. Authors reported occurrence of serious complications in 24,4% of patients with also episodes of ischemia of lower limbs after arterial cannulation.[21]

Under these circumstances, the clinical and technological implementation of ECCO<sub>2</sub>-R implemented until few years ago is closer to full extracorporeal support, than to what envisioned in the “simple” devices as described in Table 1. The more invasive and/or complex systems are characterized by: *a) flow equal or higher than 1000 ml; b) wide bore catheters; c) high doses of heparin; d) large volumes of blood to “prime” the circuit; e) numerous blood transfusion due to loss in the circuitry and from the accesses.* The rates of major complications reported in clinical studies using ECCO<sub>2</sub>-R are reported in TABLE 2B. These data help explain why ECCO<sub>2</sub>-R has been limited to the sickest patients in whom all other treatments have failed [22] and to centers with large expertise.[23, 24]

In 2009 Terragni and coworkers presented a ventilation model of very low  $V_T$  (4ml/kg of predicted body weight) for severe ARDS patients that, despite a ventilation setting derived from the *ARDSnet* Trial [4], showed morphological evidence of tidal hyperinflation.[5] This ventilatory model, that was proven to be able to decrease inflammatory markers associated with VILI, was coupled with a V-V ECCO<sub>2</sub>R device, which allowed to a safely and efficiently manage of acidosis resulted from  $V_t$  reduction. [16]

The device used in Terragni's study represents a modification of renal replacement therapy circuits, and is characterized by: *a) veno-venous by-pass systems; b) extracorporeal blood flow of 0.3-0.5 litres/min; c) smaller bore catheters or a single co-axial catheter similar to those currently used for renal ultrafiltration procedures; d) very low doses or no heparin; e) minimal volumes for "priming"*. This technological implementation of LFPPV–ECCO<sub>2</sub>-R is therefore closer to device for renal replacement therapy than full ECMO (TABLE 1) and may explain the lack of significant side effects during the use of low-flow CO<sub>2</sub> removal by-pass (TABLE 2B).

## **Chronic Obstructive Pulmonary Disease (COPD)**

ECCO<sub>2</sub>R techniques could also represent a revolutionary tool for the approach of other clinical situations like chronic obstructive pulmonary disease (COPD) exacerbations treatment in patients at risk of non-invasive ventilation failure, or the intracranial bleeding management when associated to severe ARDS. Garcia and coworkers recently presented preliminary data on the attempt to optimize ECMO in patients with COPD to reduce ventilatory support. The study reports 10 patients (mean age of 45±14 years,) treated with ECMO during weaning from all respiratory support or as bridge to lung transplant. The mean duration of extracorporeal membrane oxygenation was 20 (9–59) days, with average mean blood flows of 3.5 (1.6–4.9) L/min, and levels of CO<sub>2</sub> removal and O<sub>2</sub> transfer of 228 (54–570) mL/min and 127 (36–529) mL/min, respectively. Six of 10 patients were weaned from respiratory support or underwent transplantation and survived to discharge from the hospital. The remaining 4 patients died of sepsis and withdrawal of care.[25] (\*\*)

**Bridge to lung transplant**

ECCO<sub>2</sub>R devices with pump support, have been developed as bridges to lung transplant in patients with severe, unresponsive respiratory failure. In a recent report ECCO<sub>2</sub> R low flow devices have been proved simple and efficient methods to support patients with mild hypoxia and severe hypercapnia refractory to MV.[26](\*\*) Ruberto et al reported also the experience of veno-venous extracorporeal support in primary graft dysfunction after single lung transplant with a control of respiratory acidosis, decrease of PaCO<sub>2</sub> and reduction of ventilatory support.[27](\*\*)

## **CONCLUSIONS**

Technological improvement has permitted the creation of new devices that are able to perform extracorporeal CO<sub>2</sub> removal at lower blood flows with less invasiveness. However our knowledge is limited to case reports and case series studies. Future randomized clinical trials that will soon be initiated various studies will help physicians to consider minimally invasive extracorporeal CO<sub>2</sub> removal devices, coupled with mechanical ventilation setting as an alternative to mechanical ventilation alone to prevent and/or minimize side effects of ventilatory support.

## **BIBLIOGRAPHY**

1. Tobin MJ. Mechanical ventilation. *N Engl J Med.* 1994 Apr 14;330(15):1056-61.
2. Plataki M, Hubmayr RD. The physical basis of ventilator-induced lung injury. *Expert Rev Respir Med.* 2010 Jun;4(3):373-85.
3. Rouby J-J, Constantin J-M, Roberto De A Girardi C, et al. Mechanical ventilation in patients with acute respiratory distress syndrome. *Anesthesiology.* 2004 Jul 1;101(1):228-34.
4. ARDSnet. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med.* 2000 May 4;342(18):1301-8.
5. Terragni PP, Rosboch G, Tealdi A, et al. Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. *American journal of respiratory and critical care medicine.* 2007 Jan 15;175(2):160-6.

6. Hager DN, Krishnan JA, Hayden DL, et al. Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. *American journal of respiratory and critical care medicine*. 2005 Nov 15;172(10):1241-5.
7. Bellani G, Guerra L, Musch G, et al. Lung regional metabolic activity and gas volume changes induced by tidal ventilation in patients with acute lung injury. *Am J Respir Crit Care Med*. 2011 May 1;183(9):1193-9. (\*\*) the most innovative analysis of the correlation among the metabolic activities of lungs and mechanical stress using PET in ARDS patients.
8. Kolobow T, Gattinoni L, Tomlinson TA, et al. Control of breathing using an extracorporeal membrane lung. *Anesthesiology*. 1977 Feb;46(2):138-41.
9. Kolobow T, Gattinoni L, Tomlinson T, et al. The carbon dioxide membrane lung (CDML): a new concept. *Trans Am Soc Artif Intern Organs*. 1977;23:17-21.
10. Gattinoni L, Tognoni G, Brazzi L, et al. Ventilation in the prone position. The Prone-Supine Study Collaborative Group. *Lancet*. 1997 Sep 13;350(9080):815.

11. Pesenti A, Rossi GP, Pelosi P, et al. Percutaneous extracorporeal CO<sub>2</sub> removal in a patient with bullous emphysema with recurrent bilateral pneumothoraces and respiratory failure. *Anesthesiology*. 1990 Mar;72(3):571-3.
12. Sherlock JE, Yoon Y, Ledwith JW, et al. Respiratory gas exchange during hemodialysis. *Proc Clin Dial Transplant Forum*. 1972;2:171-4.
13. Gattinoni L, Kolobow T, Tomlinson T, et al. Control of intermittent positive pressure breathing (IPPB) by extracorporeal removal of carbon dioxide. *Br J Anaesth*. 1978 Aug;50(8):753-8.
14. Nosé Y, Malchesky PS. Therapeutic membrane plasmapheresis. 1981. *Ther Apher*. 2000 Feb 1;4(1):3-9.
15. Batchinsky AI, Jordan BS, Regn D, et al. Respiratory dialysis: Reduction in dependence on mechanical ventilation by venovenous extracorporeal CO<sub>2</sub> removal. *Critical Care Medicine*. 2011 Feb 10.
16. Terragni PP, Del Sorbo L, Mascia L, et al. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. *Anesthesiology*. 2009 Oct 1;111(4):826-35. (\*\*) Most recent report on severe ARDS patients with the use of veno-venous low flow ECCO<sub>2</sub> R device.

17. Terragni PP, Mascia LU, Urbino R, et al. Protective ventilation with CO<sub>2</sub>-removal technique in patients with ARDS. *ESICM*. 2007 Apr 13:1-.
18. Gattinoni L, Pesenti A, Caspani ML, et al. The role of total static lung compliance in the management of severe ARDS unresponsive to conventional treatment. *Intensive Care Med*. 1984 Jan 1;10(3):121-6.
19. Brunet F, Belghith M, Mira JP, et al. Extracorporeal carbon dioxide removal and low-frequency positive-pressure ventilation. Improvement in arterial oxygenation with reduction of risk of pulmonary barotrauma in patients with adult respiratory distress syndrome. *Chest*. 1993 Sep 1;104(3):889-98.
20. Morris AH, Wallace CJ, Menlove RL, et al. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO<sub>2</sub> removal for adult respiratory distress syndrome. *American journal of respiratory and critical care medicine*. 1994 Feb 1;149(2 Pt 1):295-305.
21. Bein T, Weber F, Philipp A, et al. A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. *Crit Care Med*. 2006 May 1;34(5):1372-7.

22. Lewandowski K. Extracorporeal membrane oxygenation for severe acute respiratory failure. *Crit Care*. 2000;4(3):156-68.
23. Bartlett RH, Roloff DW, Custer JR, et al. Extracorporeal life support: the University of Michigan experience. *JAMA*. 2000 Feb 16;283(7):904-8.
24. Mielck F, Quintel M. Extracorporeal membrane oxygenation. *Curr Opin Crit Care*. 2005 Feb;11(1):87-93.
25. Garcia JP, Kon ZN, Evans C, et al. Ambulatory veno-venous extracorporeal membrane oxygenation: innovation and pitfalls. *J Thorac Cardiovasc Surg*. 2011 Oct;142(4):755-61. (\*\*) It is the most innovative use of ECCO2R in rehabilitation.
26. Ricci D, Boffini M, Del Sorbo L, et al. The use of CO2 removal devices in patients awaiting lung transplantation: an initial experience. *Transplant Proc*. 2010 May;42(4):1255-8.(\*\*) Most innovative use of veno-venousECCO2R in bridge to lung transplant.
27. Ruberto F, Pugliese F, D'Alio A, et al. Extracorporeal removal CO2 using a venovenous, low-flow system (Decapsmart) in a lung transplanted patient: a case report. *Transplant Proc*. 2009 May;41(4):1412-4.

Table 1:

Extracorporeal support techniques

Table 2:

Characteristics of the LFPPV–ECCO<sub>2</sub>-R devices used in some of the largest studies from 1984 to 2009.